Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx mění a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. m. x. a č. 46/2008 Xx. m. x.

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu¹⁾.

S xxxxx xxxxxx Přílohy I xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X vstoupilo x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx X x xxxxxxxx xxx 5. xxxxxx 2019.

Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx přestalo platit xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx znění Xxxxxxx I x xxxx překlad do xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX LÁTEK X METOD XXXXXXX XXX ROK 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx text Seznamu xxxx xxxxxxxxx WADA x bude publikován x xxxxxxxxxx a xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx anglickou x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

SEZNAM XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX STÁLE (PŘI SOUTĚŽI X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (xxxx. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx po ukončené xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, včetně, xxx xx x omezením xxxxx na ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, LGD-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

Xxx xxxxx skupiny xxxx sekce: * "exogenní" xx vztahuje x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ FAKTORY, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (EPO) a xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, ale xx x omezením pouze xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, např

darbepoetiny (xXXX); erytropoetiny (EPO); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx (xxxx. XXXX 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (FG-4592); xxxxx.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. např.

asialo EPO; xxxxxxxxxxxxx XXX.

2. Peptidové xxxxxxx x hormonové xxxxxxxxxx

2.1 Choriogonadotropin (XX) x xxxxxxxxxxxx xxxxxx (XX) x jejich xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx, u xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx.

2.3 Růstový xxxxxx (XX), jeho xxxxxxxxx x xxxxxxxxxx xxxxxxx, včetně, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a xXX 176-191; hormon xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, sermorelin x xxxxxxxxxxx; sekretagogy xxxxxxxxx hormonu (XXX), xxxx. ghrelin x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; uvolňující xxxxxxx xxxxxxxxx hormonu (XXXX), xxxx. alexamorelin, XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5, XXXX-6 x xxxxxxxxx.

3. Růstové xxxxxxx a xxxxxxxxxx xxxxxxxxx faktorů, xxxxxx, xxx ne s xxxxxxxx xxxxx na xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) a xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (XXX);

xxxxxxx xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX).

Xxxxx růstové xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x vaziva, xxxxxx xxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx xxxxx xx ně):

Fenoterol; xxxxxxxxxx; xxxxxxxxx; indakaterol; xxxxxxxxxx; xxxxxxxxxx; reproterol; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; vilanterol.

Výjimkou jsou:

• inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 hodin po xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 hodin.

Přítomnost xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální výsledek xxx xxxxxxxx terapeutickou xxxxxx (x inhalaci) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx a metabolické xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx ne s xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx ně.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; a Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) xxxxxxxx xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 trimetazidin.

S5. XXXXXXXXX A XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx); xxxxxxxxxx, xxx xx s omezením xxxxx xx ně.

• Acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxx xxxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), xxx xx s omezením xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu a xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (např. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx nemá schválenou Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx jakéhokoliv původu xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx komponentami fyzikálními xxxx chemickými způsoby.

M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Pokus x Xxxxxx, xx xxxxxx porušit integritu x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) moči, xxx xx x xxxxxxxx pouze xx xx.

2. Nitrožilní xxxxxx x/xxxx injekce xxxx xxx celkem 100 xx xx 12 xxxxx kromě xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx kyselin xxxx jejich xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, vytvořených x xxxxxxxxxxx sekvencí xxxxxx x/xxxx k transkripční xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 a X1 xx M3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx stimulancia včetně xxxxx jejich případných xxxxxxxxx isomerů, např. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x omezením xxxxx xx ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx analoga (např. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního/očního xxxxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x synefrin: Xxxx xxxxx xxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2018 a xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: xx xxxxxxxx pouze xxx xxxxxxxxxxx vyšší xxx 5 xxxxxxxxxx x 1 ml xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 mikrogramů x 1 xx xxxx.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: je zakázán, xxxxx xxxx koncentrace x xxxx xx xxxxx než 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx pouze xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx s xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx apnoe, xxxxxxx xxxxxxxx na xxxx x variabilní váha.

• Střelba (XXXX, IPC)*

• Šipky (WDF)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Informace

Právní xxxxxxx x. 36/2019 Sb. m. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. s. xxx xxxxxx xxxxxxx předpisem č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, přijatá dne 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx v xxxxxxxxx xxxxx x x xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Nové xxxxx překladu Xxxxxx xx xxxxxxx xxxxxx xxxx vyhlášeno pod č. 46/2008 Sb. m. s.